10-K: Inotiv Faces Going Concern Doubt Amid Debt, Legal Costs

Inotiv, Inc. reported increased revenue but faces substantial doubt about its ability to continue as a going concern due to significant debt maturities, forecasted covenant non-compliance, and ongoing legal and cybersecurity challenges.

Summary

• Inotiv, Inc. (NOTV) reported total revenue of $513,024 thousand for the fiscal year ended September 30, 2025, an increase from $490,739 thousand in fiscal year 2024.
• Operating loss significantly decreased to $30,902 thousand in fiscal year 2025 from $86,406 thousand in fiscal year 2024.
• Net loss attributable to common shareholders decreased to $68,625 thousand in fiscal year 2025 from $108,445 thousand in fiscal year 2024.
• Net cash used in operations increased to $10,455 thousand in fiscal year 2025 from $6,805 thousand in fiscal year 2024.
• As of September 30, 2025, cash and cash equivalents were $21,741 thousand, with total debt (net of issuance costs) of $402,123 thousand.
• Management has identified conditions that raise substantial doubt about the company's ability to continue as a going concern, primarily due to significant debt maturities in the next 12 months and forecasted non-compliance with financial covenants under its Credit Agreement.
• The company completed Phase One of its site optimization plan by the end of fiscal year 2024, achieving $17,000 to $19,000 thousand in net annual cost savings.
• Phase Two of the site optimization plan is underway, expected to be completed by March 2026, with an anticipated capital investment of approximately $6,500 thousand and net annual savings of $6,000 to $7,000 thousand.
• A cybersecurity incident occurred between August 5-8, 2025, where a threat actor gained unauthorized access to systems and may have acquired data. The full operational and financial impacts are still being evaluated.
• The company entered into a Proposed Securities Settlement for $8,750 thousand and a Proposed Derivative Settlement (including $2,490 thousand from insurers and corporate governance measures) related to prior lawsuits, both subject to court approval.
• A legal settlement of $7,550 thousand was received from Freese and Nichols, Inc. (FNI) in fiscal year 2025.
• The company raised approximately $27,524 thousand in net proceeds from an underwritten public offering of common shares in December 2024.
• Management concluded that disclosure controls and procedures and internal control over financial reporting were not effective as of September 30, 2025, due to material weaknesses.

Sentiment

Score: 3

Explanation: While revenue increased and operating loss decreased, the overriding concern is the 'going concern' doubt, significant debt maturities, forecasted covenant breaches, and un-remediated material weaknesses in internal controls. These severe financial and operational challenges outweigh the positive revenue trends and legal settlements.

Positives

• Total revenue increased by 4.5% to $513,024 thousand in fiscal year 2025 from $490,739 thousand in fiscal year 2024.
• Operating loss significantly decreased by $55,504 thousand, from $86,406 thousand in fiscal year 2024 to $30,902 thousand in fiscal year 2025.
• Net loss attributable to common shareholders decreased to $68,625 thousand in fiscal year 2025 from $108,445 thousand in fiscal year 2024.
• RMS segment operating income improved significantly, from a loss of $31,929 thousand in fiscal year 2024 to an income of $20,611 thousand in fiscal year 2025, a change of $52,540 thousand.
• DSA segment revenue increased by 4.3% to $187,943 thousand, driven by biotherapeutic analysis, surgical services, and general toxicology.
• Net book-to-bill ratio for the DSA services business was 1.05x for the twelve months ended September 30, 2025, indicating new business exceeding revenue.
• DSA backlog increased to $138,197 thousand as of September 30, 2025, from $129,916 thousand at September 30, 2024.
• The company received a legal settlement of $7,550 thousand from FNI in fiscal year 2025.
• Phase One of site optimization achieved approximately $17,000 to $19,000 thousand in net annual cost savings.
• Phase Two of site optimization is expected to provide an additional $6,000 to $7,000 thousand in net annual savings and is planned for completion by March 2026, six months earlier than originally planned.
• The SEC's Division of Enforcement concluded its investigation into NHP importation practices and does not intend to recommend an enforcement action against the company.
• The company raised approximately $27,524 thousand in net proceeds from an underwritten public offering of common shares in December 2024, improving liquidity.
• Management's fiscal 2026 annual operating plan forecasts improved operating results through increases in NHP-related product and service revenue and DSA contract awards.
• The company has restored availability and access to its networks and systems following the 2025 Cybersecurity Incident.
• Management's remediation efforts for internal control weaknesses have resulted in effective design and operation of ITGCs for the DSA business and certain corporate functions, and for certain third-party hosted applications.

Negatives

• Substantial doubt exists about the company's ability to continue as a going concern due to negative operating cash flows, operating losses, net losses, significant debt maturities in the next 12 months, and forecasted non-compliance with financial covenants.
• The company had negative operating cash flows of $10,455 thousand in fiscal year 2025.
• Total debt, net of debt issuance costs, was $402,123 thousand as of September 30, 2025.
• The Term Loan Facility, Delayed Draw Term Loan, and Incremental Term Loans, totaling $268,654 thousand, mature in the next 12 months (November 2026).
• Management's fiscal 2026 annual operating plan forecasts non-compliance with financial covenants under the Credit Agreement.
• If loans are accelerated due to default, existing cash and cash equivalents, plus cash from operations, would be insufficient to repay all outstanding debt obligations.
• Disclosure controls and procedures and internal control over financial reporting were not effective as of September 30, 2025, due to material weaknesses, including IT general controls and overall COSO framework components.
• The 2025 Cybersecurity Incident resulted in unauthorized access to systems and potential data acquisition, with full operational and financial impacts still being evaluated.
• The company is a defendant in three putative class action lawsuits related to the 2025 Cybersecurity Incident, seeking monetary and injunctive relief.
• NHP importation is dependent on suppliers outside the U.S., particularly from certain countries in Southeast Asia and Africa, with legal issues related to these suppliers and increased costs due to tariffs (ranging from 10% to 20% in fiscal 2025).
• Sales of NHPs have decreased significantly in recent periods, adversely affecting business, financial condition and results of operations, and this trend may continue.
• The company is involved in legal proceedings, including the Envigo Class Action related to wage and hour requirements in California, with a proposed settlement of $795 thousand.
• The company ceased contributing to its U.S. defined contribution plans during April 2024.
• Interest expense increased by $9,709 thousand in fiscal year 2025 compared to fiscal year 2024, primarily due to additional second lien debt and revolving credit facility draws, as well as foreign exchange rate losses.
• The company's U.S. tax reporting group has a cumulative three-year loss.

Risks

• Identified conditions and events raise substantial doubt about the company's ability to continue as a going concern.
• The company has experienced periods of financial losses and hardship, with current efforts not guaranteed to result in sustained profitability.
• Significant indebtedness ($402,123 thousand net as of Sep 30, 2025) may impair the ability to raise capital or service debt, with senior term loans maturing in the next 12 months.
• The Credit Agreement contains restrictive covenants, and management forecasts non-compliance with financial covenants in fiscal 2026.
• Assets secure obligations under the Credit Agreement and Second Lien Notes and may be subject to foreclosure upon default.
• Failure to comply with Credit Agreement terms could result in an event of default, accelerating all outstanding debt (Credit Agreement, Convertible Senior Notes, Second Lien Notes).
• The company may need additional capital, which may not be available on reasonable terms or at all, potentially leading to reduced operating expenses or dilutive equity sales.
• Disclosure controls and procedures and internal control over financial reporting were not effective as of September 30, 2025, due to material weaknesses, risking inaccurate financial reporting and loss of investor confidence.
• The business is adversely affected by dependence on imported non-human primates (NHPs) from limited suppliers outside the U.S., legal issues with suppliers, increased costs (tariffs 10-20%), and inability to diversify suppliers.
• Sales of NHPs have decreased significantly, adversely affecting business and potentially continuing this trend.
• Risk of further cyber-attacks (like the 2025 Cybersecurity Incident) compromising sensitive information, disrupting operations, harming reputation, and exposing to liability (e.g., Privacy Class Actions).
• Hardware or software failures or delays in computer and communications systems could harm business, impede data processing, and result in data corruption or loss.
• Involvement in legal proceedings (employment, privacy, securities litigation, class actions) can be time-consuming, costly, and harmful to reputation.
• Some clients and contracts depend on government funding of research and development, and reductions could adversely affect business.
• Subject to inspections, investigations, and enforcement actions by regulatory authorities (FDA, USDA, U.S. Fish and Wildlife Service), potentially leading to fines, warning letters, injunctions, or license revocation.
• Subject to environmental, health, and safety requirements, potentially incurring significant costs, liabilities, and obligations (e.g., Clean Air Act, Clean Water Act, AWA, CERCLA).
• Failure to comply with existing regulations (GLP, CGMP, BE, GCP, AWA) could harm reputation, operating results, and lead to substantial penalties.
• Changes in government regulation (e.g., FDA Modernization Act 2.0 promoting alternatives to animal testing) could reduce demand for services and products.
• Failure to comply with evolving data privacy and security laws (HIPAA, international frameworks) could lead to substantial penalties, litigation, and adverse publicity.
• Changes in funding or disruptions at government agencies (e.g., FDA) could hinder product development, authorization, or normal business functions.
• Reliance on a limited number of key clients (one client accounted for 16.6% of revenue in FY2025), with loss of one or more potentially adversely affecting operating results.
• Risk of diseases in animal populations damaging inventory, harming reputation, decreasing sales, or resulting in liability.
• Operates in a highly competitive industry with many competitors having greater resources, potentially leading to price concessions.
• Majority of client contracts and orders can be terminated upon short notice, leading to fluctuations in results.
• Financial risk if contracts are underpriced or cost estimates are overrun, especially for fixed-price contracts.
• Use of potentially harmful biological and hazardous materials could injure people or violate laws, resulting in liability.
• Failure to manage growth effectively could harm business, operating results, and financial condition.
• Providing contract research services creates a risk of liability for errors and omissions or failure to care for client property.
• Development of new technologies (e.g., alternatives to animal testing, imaging, biomarker tech) could reduce demand for current products and services.
• Non-U.S. operations expose the company to risks associated with international operations (economic conditions, currency fluctuations, tax laws, regulatory differences, social unrest, difficulty enforcing agreements).
• Expansion through acquisitions exposes to risks like integration difficulties, diversion of management attention, disruption of operations, dilution, undiscovered liabilities, and retention of key personnel.
• May fail to realize anticipated strategic and financial benefits from acquisitions and site optimization strategy.
• Share price could continue to be volatile due to various factors, including going concern doubt, financial performance, and industry trends.
• Resale of common shares underlying warrants issued with Second Lien Notes could adversely affect market price and ability to raise additional equity capital.
• Anti-takeover provisions in organizational documents and Indiana law may discourage or prevent a change in control, even if beneficial to shareholders.
• Inability to maintain listing on Nasdaq Capital Market or another reputable exchange could reduce liquidity and market price.
• Actions of animal rights activists may affect business, including vandalism and targeting third parties.
• Reliance on third parties for important services, with failure potentially having a material adverse effect.
• Unfavorable general economic conditions (interest rates, inflation, recession fears, geopolitical tensions) may reduce client demand and affect ability to obtain financing.
• Pandemics, epidemics, or other public health emergencies could adversely affect business, operations, financial condition, and cash flows.

Future Outlook

Management's fiscal 2026 annual operating plan forecasts non-compliance with financial covenants under the Credit Agreement. The company believes its existing cash and cash equivalents, together with cash generated from operations, will be sufficient to fund operations and satisfy obligations for at least the next 12 months, excluding the maturity of the Term Loan Facility, Delayed Draw Term Loan, and Incremental Term Loans in November 2026. The company plans to continue efforts to optimize capital allocation and expense base, improve operating results through increases in NHP-related product and service revenue, and increase the volume of discovery and safety assessment contract awards. Revenue from long-term colony management services is expected to increase in calendar year 2026. Phase Two of the site optimization plan is expected to be completed by March 2026, providing net annual savings of $6,000 to $7,000 thousand. The company will continue to work with suppliers and customers to mitigate the financial impact of NHP tariffs and plans to invest in New Approach Methodologies (NAMs) for drug development. The company is exploring potential debt refinancing alternatives. The full operational and financial impacts of the 2025 Cybersecurity Incident are still being evaluated, and there is no assurance it will not have adverse impacts. Proposed legal settlements are subject to court approval.

Management Comments

• "Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world."
• "We are dedicated to practicing high standards of laboratory animal care and welfare."
• "Our December 2024 equity offering provided net proceeds of $27,524. This funding assisted in reducing liquidity risk and allowed us to continue to make strategic long-term decisions, while providing additional operational stability."
• "In an effort to reduce revenue volatility, we have expanded our NHP client base for calendar year 2025 and have continued to pre-sell our NHP inventory, which helped deliver a more consistent revenue stream in fiscal 2025 as compared to fiscal 2024, and we believe will continue to assist in a more consistent revenue stream for fiscal 2026."
• "We expect our revenue from our long-term colony management services to continue to increase in calendar year 2026 as compared to calendar year 2025."
• "By the end of fiscal year 2025, we believe that, as a result of Phase One and the integration of our North American transportation and distribution systems, we achieved approximately $17,000 to $19,000 in net annual cost savings."
• "We anticipate that Phase Two will require a capital investment of approximately $6,500, which includes the use of tenant improvement dollars and a portion of a settlement payment we received during March 2025. We also expect that Phase Two will reduce production capacity and create operating efficiencies, while supporting our animal welfare objectives, and provide net annual savings of $6,000 to $7,000."
• "We are in the process of executing Phase Two, which we plan to complete by March 2026, approximately six months earlier than we originally planned."
• "The Proposed Securities Settlement does not assign or reflect any admission of wrongdoing or liability by the Company or the individual defendants, all of whom deny any wrongdoing."
• "The Proposed Derivative Settlement does not assign or reflect any admission of wrongdoing or liability by the individual defendants or the Company as the nominal defendant, all of whom deny any wrongdoing."
• "While we have identified the likely scope of the incident, the full operational and financial impacts are still being evaluated. Accordingly, we have not yet determined whether the 2025 Cybersecurity Incident is reasonably likely to have a material impact on the Company."
• "We believe our future objectives are in line with the goals outlined in the FDA Modernization Act 2.0."
• "Although management believes that it will be able to implement its plan, there can be no assurances that its plan will prove successful."

Industry Context

Inotiv operates in the highly competitive contract research organization (CRO) industry, providing nonclinical and analytical drug discovery and development services, and selling research models. The industry is characterized by increasing outsourcing by pharmaceutical and biotech companies seeking efficiency and cost reduction. Demand for faster, more efficient drug development drives the need for outsourced services, especially from small and virtual companies lacking internal resources. The FDA Modernization Act 2.0 and FDA's roadmap to reduce animal testing are significant regulatory trends, prompting Inotiv to invest in New Approach Methodologies (NAMs) like computational toxicology and in vitro assays. The market for non-human primates (NHPs) has faced severe supply constraints and increased costs due to export restrictions and legal issues, impacting research model availability and pricing. Consolidation within both the pharmaceutical and CRO industries is creating opportunities for mid-market CROs that offer specialized expertise and integrated services. There is also a growing demand for robust data management and quality expertise from clients and regulators globally.

Comparison to Industry Standards

• The contract research services industry is highly competitive, with several competitors possessing significantly greater financial, marketing, technical, or other resources and a larger global footprint than Inotiv.
• For the Discovery and Safety Assessment (DSA) segment, competitors include two public companies in the U.S. and three public companies in China.
• For the Research Models and Services (RMS) segment, there are seven main competitors, including one public company in the U.S., four privately-held companies in the U.S., one government-funded, not-for-profit entity in the U.S., and one privately-held company in Europe.
• Inotiv's animal production facilities are accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International, a recognized international standard for humane animal treatment in science.
• The company's manufacturing facilities are ISO 9001:2015 certified, demonstrating adherence to international quality management standards.
• The company's investment in New Approach Methodologies (NAMs) aligns with the FDA Modernization Act 2.0 and FDA's roadmap to reduce animal testing, positioning it to adapt to evolving industry standards and regulatory expectations for drug development.
• The company's corporate governance provisions, such as a classified board and advance notice procedures, are designed to enhance continuity and stability, but may diverge from practices in other jurisdictions (e.g., Delaware) that propose higher scrutiny in response to proposed acquisitions.

Management Changes

Corporate Governance

Legal Proceedings

• **Securities Class Action**: A putative securities class action lawsuit (Grobler v. Inotiv, Inc., et al.) was filed on June 23, 2022, alleging violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5, based on alleged false and misleading statements regarding the Envigo acquisition, regulatory compliance, and non-human primate business. A proposed settlement of $8,750 thousand cash payment was reached on September 25, 2025, and preliminarily approved on October 3, 2025, with a final hearing scheduled for January 27, 2026. The company expects this to be fully funded by available insurance.
• **Derivative Actions**: Multiple shareholder derivative lawsuits were filed in 2022-2023, alleging breach of fiduciary duty, abuse of control, gross mismanagement, waste of corporate assets, and Exchange Act violations related to the Envigo acquisition and NHP business. An agreement in principle to settle was reached on September 25, 2025 (Proposed Derivative Settlement), which includes the company receiving $2,490 thousand from insurers to fund part of the Securities Class Action settlement and the institution of certain corporate governance measures for at least five years. Plaintiffs will seek attorneys' fees not exceeding $2,250 thousand, expected to be funded by insurance.
• **Privacy Class Actions**: Three putative class action lawsuits (Doyal v. Inotiv, Inc., Merrell v. Inotiv, Inc., Wagner v. Inotiv, Inc.) were filed in August-September 2025, related to the 2025 Cybersecurity Incident, alleging harm from impacted personally identifying information and protected health information. These were consolidated on October 21, 2025, and an amended consolidated complaint was filed on November 26, 2025. They seek monetary damages and injunctive relief.
• **FNI Settlement**: On February 14, 2025, the company settled a lawsuit against Freese and Nichols, Inc. (FNI) for $7,550 thousand, related to FNI's failure to design an adequately sized wastewater lagoon. The settlement payment was received prior to March 31, 2025.
• **Envigo Class Action**: Envigo is a defendant in a purported class action and a related PAGA action (Jacob Greenwell v. Envigo) filed on June 25, 2021, alleging wage and hour violations under California Labor Code. A Memorandum of Understanding to settle for $795 thousand was signed on June 2, 2023, and a Joint Stipulation of Settlement was entered on August 2, 2024. Preliminary approval was granted on June 12, 2025, with a final approval hearing scheduled for December 11, 2025.
• **SEC Investigation**: The U.S. Securities and Exchange Commission (SEC) conducted an investigation into NHP importation practices and compliance with the U.S. Foreign Corrupt Practices Act. On June 2, 2025, the SEC's Division of Enforcement provided notice that it concluded its investigation and does not intend to recommend an enforcement action against the company.
• **DOJ Resolution Agreement and Plea Agreement**: On June 3, 2024, the company reached an agreement with the DOJ to resolve a criminal investigation into its shuttered canine breeding facility. Envigo RMS pleaded guilty to one misdemeanor count of conspiracy to violate the Animal Welfare Act, and Envigo Global Services, Inc. (EGSI) pleaded guilty to one felony count of conspiracy to violate the Clean Water Act. The agreement includes total fines of $22,000 thousand (payable through June 3, 2028), $3,000 thousand to taskforces, $3,500 thousand to National Fish and Wildlife Foundation, and at least $7,000 thousand for animal welfare improvements. A Compliance Monitor was appointed on January 20, 2025, for a term of 3-5 years. Envigo and EGSI are subject to probation for up to five years.

Related Party Transactions

• **Seller Note Bolder BioPath**: An unsecured subordinated promissory note with an outstanding balance of $150 thousand as of September 30, 2025. It bears interest at 4.50% per annum, with monthly payments of principal and interest, and a maturity date of May 1, 2026.
• **Seller Payable Orient BioResource Center (OBRC)**: A payable owed by OBRC to Orient Bio, Inc. (the Seller), with an original amount of $3,700 thousand (fair value $3,325 thousand as of January 27, 2022). The maturity date has been extended multiple times, most recently to January 27, 2026. It bears interest at 4.60% per annum from July 27, 2024. The company has the right to set off indemnification obligations against this payable.

Stakeholder Impact

• **Shareholders**: Face substantial doubt about the company's ability to continue as a going concern, potential for stock price decline, dilution from future equity raises, and anti-takeover provisions that may prevent beneficial changes in control. Positively, proposed settlements for securities class action and derivative lawsuits aim to resolve litigation uncertainty, and a public offering in December 2024 provided capital.
• **Employees**: Subject to material weaknesses in internal controls and potential impacts from the cybersecurity incident. The company focuses on attracting, retaining, and developing talent through competitive compensation and benefits, and a pay-for-performance culture.
• **Customers**: May experience limitations in funding initial safety evaluations due to NHP supply issues and increased costs, and potential for delays or cancellations of contracts. The cybersecurity incident could impact client data. Positively, increased DSA backlog, expanded NHP client base, improved North American transportation, investment in New Approach Methodologies (NAMs), and a commitment to quality and scientific expertise are noted.
• **Suppliers**: Affected by NHP supply chain issues, legal issues related to NHP suppliers, and increased tariffs. The company is working with suppliers to mitigate tariff impacts.
• **Creditors**: Face substantial doubt about the company's ability to continue as a going concern, significant debt maturities in the next 12 months, forecasted non-compliance with financial covenants, and risk of default and acceleration of loans, with assets pledged as collateral. The company is exploring debt refinancing alternatives and discussing current business conditions with lenders.
• **Regulatory Authorities**: The company has faced past criminal investigations and plea agreements (Animal Welfare Act, Clean Water Act violations) and is under ongoing Compliance Monitor oversight. Material weaknesses in internal controls are also noted. Positively, the SEC concluded an NHP importation investigation without recommending enforcement action, and the company is implementing a comprehensive nationwide compliance plan.

Next Steps

• Complete Phase Two of the site optimization plan by March 2026.
• Continue efforts to optimize capital allocation and expense base.
• Improve operating results through increases in NHP-related product and service revenue and DSA contract awards.
• Continue to pre-sell NHP inventory to deliver a more consistent revenue stream for fiscal 2026.
• Increase revenue from long-term colony management services in calendar year 2026.
• Continue to work with suppliers and customers to mitigate the financial impact of NHP tariffs.
• Continue to invest in New Approach Methodologies (NAMs) for drug development.
• Remediate remaining material weaknesses in internal control over financial reporting.
• Provide notifications regarding the 2025 Cybersecurity Incident in accordance with applicable legal obligations.
• Await court approval for the Proposed Securities Settlement (final hearing January 27, 2026) and the Proposed Derivative Settlement.
• Explore potential debt refinancing alternatives.
• The Compliance Monitor will serve until January 20, 2030 (or potentially January 20, 2028 if probation ends early) to review animal care and compliance.
• The company will institute and maintain certain corporate governance measures for at least five years as part of the Proposed Derivative Settlement, including having a separate CEO and Board Chairperson, maintaining a fully independent Board Chairperson, instituting due diligence guidelines for M&A, and maintaining a disclosure committee.

Key Dates

Recommendation

The filing explicitly states "substantial doubt about our ability to continue as a going concern exists," which is a critical red flag for investors. This is compounded by management's forecast of non-compliance with financial covenants in fiscal 2026 and the maturity of over $268 million in term loans within the next 12 months, which the company admits it cannot repay with existing cash and operations if accelerated. The material weaknesses in internal controls over financial reporting further undermine confidence in the company's financial integrity. While there are some positive revenue trends and legal settlements, the magnitude of the financial distress, regulatory risks (DOJ fines, compliance monitor), and operational challenges (NHP supply, cybersecurity incident and related lawsuits) present an extremely high level of risk. The company's ability to refinance debt or raise additional capital on acceptable terms is uncertain. A seasoned investor would view these factors as overwhelmingly negative, indicating a high probability of significant capital loss.

Keywords

Contract Research Organization, Drug Discovery, Drug Development, Preclinical Research, Non-human Primates, Research Models, Biotechnology, Pharmaceutical Industry, SEC Filing, 10-K, Financial Covenants, Going Concern, Cybersecurity Incident, Legal Proceedings, Site Optimization, Debt Refinancing, Animal Welfare, Nasdaq Capital Market, NOTV